Voriconazole : a review of its use in the management of invasive fungal infections.

Abstract:

:Voriconazole (VFEND), a synthetic second-generation, broad-spectrum triazole derivative of fluconazole, inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth. In the US, intravenous and/or oral voriconazole is recommended in adults for the treatment of invasive aspergillosis, candidaemia in non-neutropenic patients, disseminated infections caused by Candida spp., oesophageal candidiasis, and in patients with scedosporiosis and fusariosis who are refractory to or intolerant of other antifungal therapy. In Europe, intravenous and/or oral voriconazole is recommended in adults and paediatric patients of at least 2 years of age for the treatment of invasive aspergillosis, candidaemia in non-neutropenic patients, fluconazole-resistant serious invasive Candida spp. infections, scedosporiosis and fusariosis. In large randomised trials, voriconazole was an effective and generally well tolerated primary treatment for candidiasis and invasive aspergillosis in adults and adolescents. More limited data also support the use of voriconazole for the treatment of invasive fungal infections in children, in those with rare fungal infections, such as Fusarium spp. or Scedosporium spp., and in those refractory to or intolerant of other standard antifungal therapies. The availability of both parenteral and oral formulations and the almost complete absorption of the drug after oral administration provide for ease of use and potential cost savings, and ensure that therapeutic plasma concentrations are maintained when switching from intravenous to oral therapy. On the other hand, the numerous drug interactions associated with voriconazole may limit its usefulness in some patients. Further clinical experience will help to more fully determine the position of voriconazole in relation to other licensed antifungal agents. In the meantime, voriconazole is a valuable emerging option for the treatment of invasive aspergillosis and rare fungal infections, including Fusarium spp. and Scedosporium spp. infections, and provides an alternative option for the treatment of candidiasis, particularly where the causative organism is inherently resistant to other licensed antifungal agents.

journal_name

Drugs

journal_title

Drugs

authors

Scott LJ,Simpson D

doi

10.2165/00003495-200767020-00009

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

269-98

issue

2

eissn

0012-6667

issn

1179-1950

pii

6729

journal_volume

67

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Emerging resistance to antimicrobial agents in gram-positive bacteria. Pneumococci.

    abstract::The prevalence of penicillin-resistant pneumococci is increasing worldwide. Methods for susceptibility testing, as well as in vitro susceptibility of penicillin-susceptible and -resistant strains to new and existing agents (including oral and parenteral streptogramins), are described. For all specimens except CSF, oxa...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600511-00003

    authors: Appelbaum PC

    更新日期:1996-01-01 00:00:00

  • Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

    abstract::Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363070-00008

    authors: Keating GM,Curran MP

    更新日期:2003-01-01 00:00:00

  • The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.

    abstract::Until recently, patients with advanced thyroid cancers had limited options for systemic treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class of targeted therapies for thyroid cancer, suddenly patients with advanced disease were given new options to extend survival. Guidelines ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-017-0733-1

    authors: Lirov R,Worden FP,Cohen MS

    更新日期:2017-05-01 00:00:00

  • The cost of treating systemic fungal infections.

    abstract::The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have been difficult to estim...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161001-00005

    authors: van Gool R

    更新日期:2001-01-01 00:00:00

  • The optimal management of hairy cell leukaemia.

    abstract::Hairy cell leukaemia is an uncommon B cell chronic lymphoproliferative disorder characterised by circulating lymphocytes displaying prominent cytoplasmic projections. Therapy is initiated for severe cytopenias or recurrent infections. Splenectomy, the first standard treatment, is now less commonly used as primary trea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549060-00006

    authors: Gollard R,Lee TC,Piro LD,Saven A

    更新日期:1995-06-01 00:00:00

  • Practical treatment guide for dose individualisation in cancer chemotherapy.

    abstract::Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological functions are proportionate to BSA, overall drug clearance is only partially related to this parameter. Consequently, following administration of equivalent drug dosages based...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856060-00006

    authors: Canal P,Chatelut E,Guichard S

    更新日期:1998-12-01 00:00:00

  • Treating ocular hypertension to reduce glaucoma risk: when to treat?

    abstract::When to treat the patient who presents with ocular hypertension has been a question that has 'stumped' the ophthalmic community for decades. Population-based studies and intervention trials have provided the basis for understanding why we consider treating such patients. Although the EGPS (European Glaucoma Prevention...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666080-00001

    authors: Higginbotham EJ

    更新日期:2006-01-01 00:00:00

  • 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

    abstract::In the mid-1980s it was discovered that serotonin (5-hydroxytryptamine; 5-HT) was at least partially responsible for producing chemotherapy-induced nausea and vomiting. It was therefore realised that serotonin receptor blockade with serotonin 5-HT3 receptor antagonists could inhibit chemotherapy-induced nausea and vom...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855020-00002

    authors: Gregory RE,Ettinger DS

    更新日期:1998-02-01 00:00:00

  • Cefadroxil in the treatment of susceptible infections in infants and children.

    abstract::The efficacy and safety of cefadroxil in the treatment of paediatric patients with a wide variety of infections were evaluated in a multicentre clinical trial. This study included 395 infants and children with Group A streptococcal pharyngitis, sinusitis, otitis media, bronchitis, pneumonia or bronchopneumonia, urinar...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600323-00005

    authors: Puhakka H,Virolainen E

    更新日期:1986-01-01 00:00:00

  • Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.

    abstract::Levocabastine is a potent and selective histamine H1-receptor antagonist which has been evaluated as a topical treatment (nasal spray and/or eyedrops) for allergic rhinitis and/or conjunctivitis. Data available at the time of the previous review in Drugs, together with more recent results, have clearly demonstrated th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550060-00009

    authors: Noble S,McTavish D

    更新日期:1995-12-01 00:00:00

  • Long-term growth hormone replacement therapy in hypopituitary adults.

    abstract::Growth hormone deficiency (GHD) in the adult has now been fully recognised as a clinical entity characterised by abnormal body composition, osteopenia, impaired quality of life, cardiac dysfunction and an adverse lipid profile. While short-term studies of GH replacement have demonstrated irrefutably a favourable effec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262160-00006

    authors: Verhelst J,Abs R

    更新日期:2002-01-01 00:00:00

  • Canagliflozin: first global approval.

    abstract::Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0064-9

    authors: Elkinson S,Scott LJ

    更新日期:2013-06-01 00:00:00

  • Pharmacokinetics of ofloxacin in patients on haemodialysis treatment.

    abstract::Serum concentrations and pharmacokinetic parameters of ofloxacin were measured in 10 patients on haemodialysis treatment. Serum half-life during the interdialytic interval was 48 hours, and during haemodialysis treatment 10 hours. The decrease in serum concentrations during a 4-hour haemodialysis was 25%. After severa...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700341-00014

    authors: Dörfler A,Schulz W,Burkhardt F,Zichner M

    更新日期:1987-01-01 00:00:00

  • Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

    abstract::Acyclovir (aciclovir) is a nucleoside antiviral drug with antiviral activity in vitro against members of the herpes group of DNA viruses. As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of acyclovir provide significant therapeutic benefit in genita...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198937030-00002

    authors: O'Brien JJ,Campoli-Richards DM

    更新日期:1989-03-01 00:00:00

  • A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.

    abstract:BACKGROUND:Opioid pharmacotherapies play an important role in the treatment of opioid-dependent women; however, very little is known about the safety of naltrexone in pregnant patients. OBJECTIVE:This study examined the obstetric health of opioid-dependent women who were treated with implant naltrexone during pregnanc...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.1007/s40265-017-0762-9

    authors: Kelty E,Hulse G

    更新日期:2017-07-01 00:00:00

  • Antirheumatic drugs: clinical pharmacological and therapeutic aspects.

    abstract::There are many current concepts of the pathogenesis of rheumatic diseases which incorporate immunological, infectious and hereditary factors. Rheumatic diseases may sometimes become apparent after trauma, be associated with certain diseases and may be induced by nerve damage and serum sickness. Systemic lupuserythemat...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197510050-00008

    authors: Smyth CJ,Bravo JF

    更新日期:1975-01-01 00:00:00

  • Continuous-use ethinylestradiol/levonorgestrel 20microg/90microg: as an oral contraceptive.

    abstract::The continuous-use combination oral contraceptive ethinylestradiol/levonorgestrel 20microg/90microg suppresses gonadotropins, and subsequently ovulation and endometrial thickening, and suppresses breakthrough bleeding. Amenorrhoea and absence of breakthrough bleeding increase in incidence with extended administration....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767160-00010

    authors: Wagstaff AJ

    更新日期:2007-01-01 00:00:00

  • Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

    abstract::Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis, while maintaining low...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363220-00015

    authors: Cheer SM,Waugh J,Noble S

    更新日期:2003-01-01 00:00:00

  • Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?

    abstract::Janus kinase (JAK) is a signal transducer and activator of a protein transcription system that transduces signals from cell surface cytokine and growth factor receptors to the nucleus. Recently developed JAK inhibitors (JAKinibs) inhibit JAKs non-selectively or selectively and down-regulate the effects of correspondin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01349-1

    authors: Harigai M,Honda S

    更新日期:2020-08-01 00:00:00

  • The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

    abstract::Tuberous sclerosis complex (TSC) is a genetic disorder arising from mutations in the TSC1 or TSC2 genes. The resulting over-activation of the mammalian target of rapamycin (mTOR) signalling pathway leaves patients with TSC susceptible to the growth of non-malignant tumours in multiple organs. Previously, surgery was t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0552-9

    authors: Curatolo P,Bjørnvold M,Dill PE,Ferreira JC,Feucht M,Hertzberg C,Jansen A,Jóźwiak S,Kingswood JC,Kotulska K,Macaya A,Moavero R,Nabbout R,Zonnenberg BA

    更新日期:2016-04-01 00:00:00

  • Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).

    abstract::Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345040-00002

    authors: Sandström E,Oberg B

    更新日期:1993-04-01 00:00:00

  • Overview of the worldwide problem of diarrhoea.

    abstract::Acute infectious diarrhoea is the major killer of children in the Third World. It is also the principal cause of malnutrition in children under 5 years of age. More than 4 million children die each year of diarrhoea and its complications. Acute diarrhoea kills by causing dehydration, which leads to hypovolaemia and me...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800364-00003

    authors: Gold R

    更新日期:1988-01-01 00:00:00

  • The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia.

    abstract::This paper reviews the use of the fluoroquinolone antibiotics in the management of sexually transmitted diseases (STD) in Southeast Asia. Numerous clinical trials performed in the region have shown that the quinolones are highly effective for treating uncomplicated gonorrhoea. Norfloxacin 800 mg, ofloxacin 400 mg, cip...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00019

    authors: Sivayathorn A

    更新日期:1995-01-01 00:00:00

  • Brodalumab: First Global Approval.

    abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0634-8

    authors: Greig SL

    更新日期:2016-09-01 00:00:00

  • Management of onychomycoses.

    abstract::Onychomycoses, infections of the nail caused by fungi, are amongst the most common illnesses. Because of the high incidence of these infections and problems involved in their therapy, they have received much attention, particularly as concerns a better characterisation of the causative micro-organisms. Onychomycosis c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958020-00005

    authors: Niewerth M,Korting HC

    更新日期:1999-08-01 00:00:00

  • Value of non-drug treatment and drug treatment in hypertension.

    abstract::The benefits of the treatment of hypertension currently consist of a substantially reduced incidence of premature stroke, left ventricular failure and malignant hypertension. The benefits for the individual are most clearcut in those who have already had severe or symptomatic hypertension. Older subjects who have a hi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800366-00003

    authors: Beilin LJ

    更新日期:1988-01-01 00:00:00

  • Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

    abstract::Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy. Since the publication of this original review, further studies have been published that show ond...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345060-00006

    authors: Markham A,Sorkin EM

    更新日期:1993-06-01 00:00:00

  • Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

    abstract::Although vasodilator drugs are of proven worth in the management of patients with severe heart failure, a useful system of classification of vasodilator drugs has not yet been devised. The traditional system of classification based on the dominant arterial and/or venous sites of action as determined by limb plethysmog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224010-00003

    authors: Packer M

    更新日期:1982-07-01 00:00:00

  • Tipranavir: a review of its use in the management of HIV infection.

    abstract::Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durab...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868100-00006

    authors: Orman JS,Perry CM

    更新日期:2008-01-01 00:00:00

  • The funny current: cellular basis for the control of heart rate.

    abstract::The 'funny' (pacemaker, I(f)) current, first described almost 30 years ago in sinoatrial node (SAN) myocytes, is a mixed sodium/potassium inward current, activated on hyperpolarisation in the diastolic range of voltages. 'Funny' (f) channels are activated by intracellular cyclic adenosine monophosphate (cAMP) concentr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767002-00003

    authors: DiFrancesco D,Borer JS

    更新日期:2007-01-01 00:00:00